Alto Neuroscience, Inc.
ANRO
$27.04
$1.746.88%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -17.60% | -2.94% | -8.37% | -30.23% | -48.88% |
| Total Depreciation and Amortization | 17.01% | 31.67% | 51.80% | 64.16% | 50.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.80% | 14.08% | 24.25% | 45.80% | 94.26% |
| Change in Net Operating Assets | 186.92% | -99.19% | -170.16% | -156.15% | -1,595.65% |
| Cash from Operations | -17.56% | -9.16% | -16.00% | -31.25% | -43.60% |
| Capital Expenditure | 70.35% | 98.84% | 72.41% | -60.06% | -178.60% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 70.35% | 98.84% | 72.41% | -60.06% | -178.60% |
| Total Debt Issued | -96.42% | 1,535.04% | 1,535.04% | -- | -- |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | 45,369.60% | -63.20% | -99.71% | -99.77% | -99.73% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -515.81% | 74.44% | 86.92% | 101.27% | 83.45% |
| Cash from Financing | 1,517.04% | -55.72% | -94.44% | -93.74% | -94.23% |
| Foreign Exchange rate Adjustments | 14.29% | -172.73% | -76.92% | -316.67% | -566.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 330.75% | -90.42% | -133.52% | -133.83% | -131.86% |